Skip to main content

In Vitro Identification of Cytochrome P450 Enzymes Responsible for Drug Metabolism

  • Protocol
  • First Online:
Pharmacogenomics

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1015))

Abstract

Metabolism catalyzed by the cytochrome P450 enzymes (CYPs) represents the most important pathway for drug metabolism and elimination in humans. Identification of the CYPs responsible for metabolism of existing and novel drugs is critical for the prediction of adverse reactions caused by drug–drug interactions or individual genetic polymorphism. An integrated approach is described for CYP-mediated metabolic reaction phenotyping using both recombinant enzymes and human liver microsomes in combination of selective inhibitors or inhibitory antibodies. The in vitro method described includes screening of recombinant CYPs for metabolic activity, chemical inhibition or antibody neutralization, and correlation analysis with isoform-selective marker activities. The primary focus is on identification of the most common enzymes including CYP1A2, 2C9, 2C19, 2D6, and 3A4, although the same strategy could potentially be used for identification of other isoforms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lin JH, Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403–449

    PubMed  CAS  Google Scholar 

  2. Yan Z, Caldwell GW (2001) Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem 5:403–425

    Google Scholar 

  3. Rannug A, Alexandrie A-K, Persson I, Ingelman-Sundberg M (1995) Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 37:25–36

    Article  PubMed  CAS  Google Scholar 

  4. Murray M (2006) Role of CYP pharmacogenetics and drug–drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 58:871–885

    Article  PubMed  CAS  Google Scholar 

  5. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS-E, Mizugaki M (2002) Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 53:596–603

    Article  PubMed  CAS  Google Scholar 

  6. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526

    Article  PubMed  CAS  Google Scholar 

  7. Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, Lu AYH (2011) Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 36:1–16

    Article  PubMed  CAS  Google Scholar 

  8. Vermeir M, Hemeryck A, Cuyckens F, Francesch A, Bockx M, Van Houdt J, Steemans K, Mannens G, Aviles P, De Coster R (2009) In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 77:1642–1654

    Article  PubMed  CAS  Google Scholar 

  9. Yan Z, Caldwell GW (2004) Evaluation of cytochrome P450 inhibition in human liver microsomes. Optimization in Drug Discovery, Humana, Totowa, NJ, pp 231–244

    Google Scholar 

  10. Zhang H, Davis CD, Sinz MW, Rodrigues AD (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667–687

    Article  PubMed  CAS  Google Scholar 

  11. Harper TW, Brassil PJ (2008) Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 10:200–207

    Article  PubMed  CAS  Google Scholar 

  12. Kumar V, Rock DA, Warren CJ, Tracy TS, Wahlstrom JL (2006) Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 34:1903–1908

    Article  PubMed  CAS  Google Scholar 

  13. Yan Z, Caldwell GW, Wu W, McKown L, Rafferty B, Jones W, Masucci JA (2002) In vitro identification of metabolic pathways and cytochrome P450 isoforms involved in the metabolism of etoperidone. Xenobiotica 32(11):949–962

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Yan, Z., Caldwell, G.W. (2013). In Vitro Identification of Cytochrome P450 Enzymes Responsible for Drug Metabolism. In: Innocenti, F., van Schaik, R. (eds) Pharmacogenomics. Methods in Molecular Biology, vol 1015. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-435-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-435-7_16

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-434-0

  • Online ISBN: 978-1-62703-435-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics